An oncology nurse shares advice for avoiding exhaustion and soreness when administering subcutaneous injections.

For the first time in Canada, a patient has received cancer immunotherapy by subcutaneous (under the skin) injection in their ...

New formulation supports adaptable care delivery in oncology settings with limited capacity or remote patient populations ...

Objective: To describe the evidence in the literature regarding the knowledge and practices of the nursing team about subcutaneous administration ... should be in liquid form and diluted in water for ...

Safety profiles were comparable, with fewer treatment-related side effects in the subcutaneous group, though local injection site reactions were more common ... presented during the 50 th Annual ...

In the subcutaneous injection group, after 24 hours, the nurse measured bruise size with a millimeter ruler ... according to the units prescribed to the patient. The application site was determined ...

complementing the successful Phase 3 Subcutaneous Olanzapine Extended-Release Injection Study (SOLARIS) evaluating TEV-'749. More than 92% of patients, 87% of nurses and 72% of physicians were ...

Ultra-long-acting subcutaneous (SQ ... including QTc intervals), and physical exams. Most injection site reactions of ASC30 were mild. There were no Grade 3 or higher injection site reactions.

A doctor or oncological nurse inserts the needle into ... maintenance of a surgical port. Although injection site reactions are still possible, subcutaneous injections are considered less painful ...

"Injections were generally well tolerated, with injection-site pain being the most common ... safe and effective administered in twice-yearly subcutaneous injections in the phase III PURPOSE ...

like elderly patients Causing less pain at the injection site Minimizing skin irritation and lesions Preventing the medication from leaking into the patient’s subcutaneous tissue Sealing the ...